Buzzers Cat’s Claw: Hidden Opioids, Lab Findings, Dependence, Withdrawal & Safety Monograph

Buzzers Cat’s Claw: Hidden Opioids, Lab Findings, Dependence, Withdrawal & Safety Monograph

Emergency warning: Utah authorities specifically warned consumers not to use Buzzers-branded Cat’s Claw tablets after tested products were found to contain opioid-active compounds. If someone cannot be awakened, has slow, shallow, irregular or stopped breathing, has blue/gray lips, makes choking or gurgling sounds while unresponsive, or collapses after taking one of these products, call 911 and administer naloxone if available.

Product history and investigation timeline

Buzzers became a public-health issue in 2026, when poison-center reports of unexpected opioid-like toxicity involving products marketed as Cat's Claw/Kava-style botanicals were followed by product-specific investigation in Utah.

The evidence sequence matters:

1. Clinical signal: poison centers received reports of severe opioid-like effects from products sold under botanical branding.
2. Named-product warning: Utah Poison Control publicly identified Buzzers among products of concern.
3. Laboratory confirmation: Utah authorities reported that tested Buzzers Cat's Claw tablets contained MGM-15 and mitragynine pseudoindoxyl.
4. Regulatory change: mitragynine pseudoindoxyl and MGM-15 entered temporary federal Schedule I control on August 26, 2026.

That timeline explains why older packaging, certificates, retailer descriptions, forum posts, or archived webpages can conflict with later toxicology and legal findings. A product-market history is not a guarantee that every lot had the same composition.

Quick answer

In July 2026, the Utah Department of Agriculture and Food (UDAF) and the Utah Poison Control Center (UPCC) reported that tested Buzzers Cat’s Claw tablets contained MGM-15 and mitragynine pseudoindoxyl.

That is the central confirmed fact.

Neither compound is a normal constituent of genuine Cat’s Claw (Uncaria tomentosa). Both belong to the emerging opioid-active kratom-derivative market.

The official warning followed:

• a recent death under investigation;
• several severe health incidents;
• overdose cases involving multiple Buzzers flavors.

Utah authorities told the public not to buy or consume the products and told retailers to remove them. UDAF, July 30 2026

The evidence does not prove that every Buzzers tablet ever sold contains the same chemicals.

It does prove that a product presented as Cat’s Claw entered ordinary retail channels while containing undisclosed opioid-active drugs.

---

The four evidence lanes: do not mix them up

Gray-market product reporting becomes misleading when different evidence types are collapsed together.

1. Laboratory-confirmed contents

For tested Buzzers Cat’s Claw tablets in the Utah investigation, UDAF reported:

• MGM-15 / dihydro-7-hydroxymitragynine
• mitragynine pseudoindoxyl

That is the strongest product-specific evidence.

2. Poison-center/public-health suspicion

Before the laboratory announcement, UPCC warned about severe opioid overdose, dependence and withdrawal involving smoke-shop products labeled with Cat’s Claw or Kava.

The alert named Buzzers and Homiez but said other brands could be involved.

UPCC suspected compounds including:

• 7-hydroxymitragynine;
• mitragynine pseudoindoxyl;
• MGM-15;
• MGM-16.

The poison-center alert did not establish that every listed brand contained every suspected compound.

3. Manufacturer/retailer label claims

A package can claim:

• Cat’s Claw;
• Kava;
• botanical extract;
• no kratom;
• no 7-OH.

Those are claims, not analytical findings.

4. User reports

People online may report:

• opioid-like sedation;
• a “nod”;
• tolerance;
• withdrawal;
• effects similar to 7-OH or another opioid.

Those reports are useful early-warning signals.

They cannot identify the molecule.

This four-lane separation should be the standard for every smoke-shop product on this site.

---

What Utah actually found

On July 30, 2026, UDAF reported that Buzzers-branded Cat’s Claw tablets investigated after a death and multiple severe health incidents contained MGM-15 and mitragynine pseudoindoxyl.

UDAF said:

• the compounds were found in multiple flavors;
• they had been identified in recent overdose cases;
• the products were illegally sold in Utah;
• genuine Cat’s Claw should not contain kratom-derived psychoactive compounds.

This was not a theoretical concern based on package appearance.

It was a government-reported laboratory finding. UDAF

---

What we still do NOT know about Buzzers

Public evidence does not establish:

• the composition of every lot;
• the concentration in every tablet;
• whether every flavor has the same formulation;
• whether older and newer packages are chemically identical;
• whether additional compounds were present below the scope of a published test;
• whether products sold in other states had identical composition;
• whether later reformulations changed after the Utah warning;
• whether every severe event was caused by the same chemical profile.

That uncertainty is important.

A recall or laboratory finding can make a product more concerning without making every package chemically identical.

---

What genuine Cat’s Claw is

Cat’s Claw usually refers to Uncaria tomentosa, a woody vine from Central and South America.

It has been marketed as a botanical supplement and investigated primarily for anti-inflammatory and immunologic effects.

Genuine Cat’s Claw is not an opioid product.

It should not normally produce a classic opioid toxidrome such as profound sedation plus slowed breathing.

That makes the branding especially misleading.

A shopper can reasonably interpret “Cat’s Claw extract” as an herbal product when the actual pharmacology of a mislabeled tablet may be dominated by opioid agonists.

---

What Kava is—and why the label can also confuse people

Kava (Piper methysticum) is a psychoactive plant with sedative/anxiolytic effects.

It is not an opioid.

Kava itself can cause drowsiness and impaired coordination, which creates a dangerous interpretive problem if an undisclosed opioid is also present: a person may mistake excessive opioid sedation for “strong kava.”

CDC poison-center surveillance also shows a broader rise in serious medical outcomes involving commercial Kava products and increasing co-use with kratom. PMID 41926333

That national kava surveillance does not prove hidden opioids caused every Kava-related event.

It provides context for why this retail category needs better monitoring.

---

MGM-15: what it is

MGM-15 is another name for dihydro-7-hydroxymitragynine.

It is a semi-synthetic derivative related to 7-hydroxymitragynine.

A 2025 peer-reviewed analysis of commercial MGM-15 tablets confirmed marketed MGM-15 material and documented strong opioid-receptor binding. PMID 40936282

Human evidence remains poor

There are no controlled human trials establishing:

• safe exposure;
• pharmacokinetics;
• respiratory-depression threshold;
• dependence timeline;
• withdrawal severity;
• interaction magnitude;
• long-term toxicity.

That means a product containing MGM-15 can have strong opioid pharmacology while still being clinically under-characterized.

See the MGM-15 monograph.

---

Mitragynine pseudoindoxyl: what it is

Mitragynine pseudoindoxyl is a rearranged compound related to mitragynine/7-OH chemistry.

Preclinical studies support potent mu-opioid receptor agonism with additional delta-receptor pharmacology. Váradi et al.

Human plasma experiments also demonstrate conversion of 7-OH to pseudoindoxyl under experimental conditions. PMID 33344889

Human withdrawal is now documented

A 2026 case report described severe opioid-like withdrawal after regular mitragynine pseudoindoxyl use. PMID 41982589

That matters enormously for Buzzers because one of the compounds Utah actually found is now associated with direct human withdrawal evidence.

See the mitragynine pseudoindoxyl monograph.

---

Why “no kratom” can be misleading

“Kratom” is often used loosely to mean traditional Mitragyna speciosa leaf or its common alkaloids.

A product could theoretically contain no botanical leaf and no measurable mitragynine yet still contain a semi-synthetic derivative produced from kratom-related chemistry.

So a “no kratom” claim does not answer:

• Is MGM-15 present?
• Is mitragynine pseudoindoxyl present?
• Is MGM-16 present?
• Is another opioid present?

The claim may be rhetorically reassuring while chemically incomplete.

---

Why “no 7-OH” can also be misleading

7-hydroxymitragynine is one specific molecule.

MGM-15 and mitragynine pseudoindoxyl are different molecules.

A product can therefore test negative for 7-OH while still containing another opioid-active kratom derivative.

No 7-OH does not mean no opioid.

---

How to read a certificate of analysis without being fooled

A certificate of analysis is only as informative as:

• the sample actually tested;
• the laboratory's method;
• the analyte list;
• the detection limit;
• the date;
• the chain of custody;
• whether the tested lot matches the product in hand.

“ND” does not mean “nothing is there”

ND / non-detect normally means:

the named analyte was not detected above the method's reporting threshold.

It does not mean:

• no psychoactive drug;
• no opioid;
• no novel derivative;
• no compound outside the testing panel.

Questions that matter

When looking at a COA, ask:

1. Was MGM-15 specifically tested?
2. Was mitragynine pseudoindoxyl specifically tested?
3. Was MGM-16 tested?
4. Was 7-OH tested?
5. Were fentanyl/nitazenes/other novel opioids included?
6. Does the lot number match the package?
7. Is the lab independent?
8. Are quantitative results and reporting limits shown?
9. Was the method validated for those analytes?

A narrow alkaloid panel cannot prove broad chemical safety.

---

Overdose: what to look for

A hidden opioid can produce:

• inability to stay awake;
• inability to wake;
• slow, shallow or irregular breathing;
• stopped breathing;
• blue/gray lips;
• limpness;
• choking, snoring or gurgling while unresponsive;
• pinpoint pupils;
• collapse.

Do not wait for every sign.

A person can have severe opioid toxicity without obvious pinpoint pupils.

---

Naloxone

UPCC specifically recommended naloxone in suspected overdoses involving these products.

Naloxone can reverse opioid effects.

It is appropriate when a hidden opioid is possible even when the exact compound is unknown.

Important limitation

Naloxone is not a substitute for emergency care.

A person can:

• become sedated again;
• have another drug on board;
• aspirate;
• have suffered low oxygen before reversal.

Call 911 for severe overdose signs.

---

Tolerance and physical dependence

If a product repeatedly delivers a potent MOR agonist, opioid tolerance and physical dependence are biologically plausible.

For mitragynine pseudoindoxyl, dependence/withdrawal is supported by direct human case evidence.

For MGM-15, direct human dependence studies remain lacking.

That distinction should be preserved.

What dependence can look like

A person may notice:

• needing the product to feel normal;
• escalating frequency;
• waking at night because symptoms begin;
• anxiety/restlessness as effects wear off;
• gastrointestinal symptoms;
• sweating/chills;
• muscle aches;
• insomnia;
• strong urge to take another tablet.

The user may initially interpret this as “the supplement wearing off” rather than opioid withdrawal.

---

Withdrawal

Because the actual product composition may be unknown, Buzzers withdrawal cannot be reduced to a single predictable timeline.

If pseudoindoxyl or another strong opioid is driving dependence, symptoms may resemble opioid withdrawal:

• restlessness;
• sweating;
• chills;
• anxiety;
• insomnia;
• abdominal cramps;
• nausea/vomiting;
• diarrhea;
• muscle aches;
• rapid pulse;
• craving.

No validated Buzzers taper exists

There is no evidence-based Buzzers tablet taper schedule.

A label-based taper is especially problematic because:

• tablet content may be inconsistent;
• formulations may change;
• the actual opioid may be unknown;
• more than one active drug may be present.

Medical or addiction-specialist assessment is safer when regular use has produced dependence.

---

Dependence vs addiction

Physical dependence means the nervous system has adapted and withdrawal occurs when exposure falls.

Opioid use disorder involves a wider pattern of impaired control or continued use despite harm.

Warning signs of a developing substance-use problem include:

• repeated unsuccessful attempts to stop;
• escalating use;
• craving;
• overdoses;
• using despite work, family or health problems;
• using in dangerous situations;
• spending substantial time obtaining/recovering;
• tolerance and withdrawal.

Someone can become physically dependent on a mislabeled product without knowingly choosing an opioid.

That distinction is particularly important here.

---

Treatment and support

There is no approved treatment protocol specifically for “Buzzers dependence.”

The clinically relevant framework is opioid withdrawal / opioid use disorder care when an opioid-active product is suspected.

Utah's own public-health warning advised people experiencing dependence or withdrawal to speak with an addiction specialist.

Care may include:

• medical assessment;
• treatment of dehydration or complications;
• evaluation for opioid use disorder;
• established opioid-use-disorder medications when clinically appropriate;
• behavioral support;
• relapse/overdose prevention;
• naloxone access.

This site does not provide a do-it-yourself opioid taper based on an unverified product label.

For U.S. treatment resources, FindTreatment.gov can locate addiction services, and SAMHSA's National Helpline is 1-800-662-HELP (4357).

---

The broader pseudoindoxyl / 7-OH product market

Buzzers did not emerge in isolation.

A 2025 study found 304 online products marketed as containing 7-OH and/or mitragynine pseudoindoxyl. PMID 40373645

Another study identified 51 unique pseudoindoxyl-containing products, many with consumer-friendly branding; only a minority of websites explicitly disclosed opioid-receptor activity. PMID 40568898

This retail environment creates a major communication problem:

products with opioid pharmacology can be marketed using the visual language of supplements, wellness products, candy, herbal extracts or legal highs.

---

Poison-center context: kratom and Kava products were already trending upward

CDC analyses published in 2026 documented:

• a large increase in kratom-related poison-center reports during 2015–2025;
• growing Kava exposure reports;
• increased Kava + kratom co-use;
• higher rates of serious outcomes in recent years.

Those surveillance datasets predate or extend beyond the specific Buzzers investigation.

They should not be used to claim Buzzers caused the national trend.

They show that the commercial botanical/extract market was already changing quickly enough to challenge ordinary poison surveillance.

---

Legal status — verified October 2, 2026

Utah

UDAF stated that MGM-15 and mitragynine pseudoindoxyl found in Buzzers were Schedule I drugs under Utah law and that Utah had prohibited kratom products other than pure-leaf products during the 2026 legislative session.

United States federal law

DEA temporarily placed:

• mitragynine pseudoindoxyl;
• MGM-15;
• MGM-16

into Schedule I effective August 26, 2026 through August 26, 2028, unless the order is extended or replaced. Federal Register

Retail sale to the general public of those Schedule I substances is not permitted under the Controlled Substances Act.

Legal status is date- and jurisdiction-specific and can change.

---

What about Homiez?

UPCC's July 22 alert named Buzzers and Homiez among Cat’s Claw/Kava products associated with severe overdose reports.

The evidentiary distinction matters:

• Buzzers: UDAF later published a specific lab result identifying MGM-15 and mitragynine pseudoindoxyl in tested products.
• Homiez: the poison-center warning identified the brand in the broader concern, but the cited public alert did not publish an equivalent brand-wide lab result establishing the same exact compounds.

So this site will not say “Homiez contains MGM-15” unless a specific analytical result supports that statement.

---

What Reddit and user reports are good for

Community discussions can reveal:

• an unexpected opioid-like effect;
• sudden tolerance;
• withdrawal after frequent use;
• a new brand spreading across smoke shops;
• changing packaging;
• claims such as “no kratom” or “no 7-OH.”

Those are useful signals.

They can justify:

• poison-center investigation;
• analytical testing;
• product surveillance;
• a new evidence page.

They cannot determine the active molecule.

A person cannot reliably distinguish MGM-15 from pseudoindoxyl, 7-OH, a nitazene, fentanyl, or a mixture by subjective effects.

---

Common myths

“Cat’s Claw is an herb, so the tablets cannot be opioids.”

False for a mislabeled/adulterated product. Utah testing found opioid-active drugs in Buzzers Cat’s Claw tablets.

“The package says no kratom.”

That does not rule out a kratom-derived semi-synthetic opioid.

“The package says no 7-OH.”

That only addresses one molecule.

“The COA says ND.”

Only for the analytes actually included in that test.

“I would know if it contained an opioid.”

Not necessarily. Dependence can develop before someone recognizes the pharmacologic class.

“If naloxone works, the product must have contained fentanyl.”

No. Naloxone reverses many opioid agonists, including non-fentanyl opioids.

“All Buzzers are proven to contain MGM-15 and pseudoindoxyl.”

No. The official finding applies to tested products from the Utah investigation.

---

What is established vs unknown

Established

• tested Utah Buzzers Cat’s Claw tablets contained MGM-15 and mitragynine pseudoindoxyl;
• those compounds are opioid-active and are not normal Cat’s Claw constituents;
• severe health incidents and a death were under investigation in connection with the products;
• UPCC warned of overdose, dependence and withdrawal;
• MGM-15 and pseudoindoxyl are federally Schedule I as of August 26, 2026;
• pseudoindoxyl has direct human withdrawal evidence.

Probable

• repeated exposure to a product containing potent opioid agonists can produce opioid tolerance and physical dependence;
• polysubstance exposure can make overdose worse;
• labels that omit the active opioid make recognition and treatment harder.

Not established

• the contents of every Buzzers lot ever sold;
• a universal Buzzers tablet concentration;
• a safe dose;
• a typical time to dependence;
• a Buzzers-specific withdrawal timeline;
• a validated Buzzers taper;
• that every Homiez or Cat’s Claw/Kava product contains the same compounds.

---

If someone has been using these products regularly

A few questions matter more than the brand name:

• Do you need it to avoid feeling sick?
• Are you waking up in withdrawal?
• Has use become more frequent?
• Have you had an overdose or severe sedation?
• Are you mixing it with alcohol, benzodiazepines or other opioids?
• Have you tried to stop and been unable to?
• Are you unsure what is actually in the product?

Those are reasons to seek medical/addiction support.

If severe sedation or abnormal breathing is happening right now, that is an emergency rather than a routine withdrawal question.

---

Special populations

There are no controlled safety studies of Buzzers or similar hidden-opioid botanical-branded products in pregnancy, breastfeeding, adolescents, older adults, chronic respiratory disease, seizure disorders, or significant liver/kidney disease.

The uncertainty is greater than for a single known drug because the product composition itself can be uncertain.

Particular concern applies when:

• an opioid-naive person unknowingly receives a potent opioid agonist;
• pregnancy or breastfeeding makes fetal/infant exposure clinically relevant;
• sleep apnea, COPD, or other respiratory disease reduces physiologic reserve;
• older age, frailty, or sedating medications increase fall/airway risk;
• liver or kidney disease may alter exposure to one or more unidentified active compounds.

These are risk considerations, not quantified Buzzers-specific probabilities.

Bottom line

Buzzers Cat’s Claw is one of the clearest recent examples of why branding is not chemical identity.

The strongest evidence is unusually concrete:

Utah authorities reported that tested Buzzers Cat’s Claw tablets contained MGM-15 and mitragynine pseudoindoxyl.

From there, the safest conclusions are:

• treat opioid-like symptoms as opioid toxicity regardless of the label;
• recognize dependence and withdrawal as possible;
• do not trust “no kratom,” “no 7-OH,” or a narrow COA as proof of no opioid;
• distinguish tested Buzzers findings from broader suspicions about other brands;
• remember that gray-market formulations can change;
• use addiction/medical support rather than an improvised taper when dependence develops.

For harm reduction, this product category should be approached as an identity-uncertain opioid market hidden inside botanical branding.

Related evidence

• Cat’s Claw & Kava products with hidden opioids
• MGM-15 monograph
• Mitragynine pseudoindoxyl
• 7-Hydroxymitragynine
• MGM-16
• Kratom / 7-OH withdrawal evidence
• Substance Use, Dependence & Harm Reduction hub